(Q35613758)

9 August 2017

1 reference

title

Treatment of non-schizophrenic disorders: focus on atypical antipsychotics (English)

1 reference

9 August 2017

0 references

1

Dilip V Jeste

1 reference

9 August 2017

2

Christian R Dolder

1 reference

9 August 2017

publication date

1 January 2004

1 reference

Journal of Psychiatric Research

9 August 2017

published in

1 reference

9 August 2017

volume

38

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

73-103

1 reference

Olanzapine in the treatment of depressive disorders with psychotic symptoms

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Risperidone for psychotic and behavioural symptoms in Lewy body dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

A case report of risperidone-induced obsessive-compulsive symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Response to clozapine in acute mania is more rapid than that of chlorpromazine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Induction of mania by risperidone resistant to mood stabilizers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Olanzapine compared to lithium in mania: a double-blind randomized controlled trial

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

7 January 2021

Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Development of Obsessive-Compulsive Symptoms during Clozapine Treatment in Schizophrenia and Its Positive Response to Clomipramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Neuroleptic sensitivity to clozapine in dementia with Lewy bodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Clozapine for treatment-refractory mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Clozapine use in diffuse Lewy body disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Nonpharmacologic Interventions for Inappropriate Behaviors in Dementia: A Review, Summary, and Critique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Hypothalamic-pituitary-adrenal axis hyperactivity and psychosis: recovery during an 8-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

The clinical and neuroendocrine features of psychotic depression.

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

7 January 2021

Importance of psychotic features to long-term course in major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Treatment of psychotic depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Psychosis, behavioral disturbance, and the use of neuroleptics in dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Clinical utility of clozapine in 16 patients with neurological disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Quetiapine for treatment-resistant mania.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Risperidone treatment for juvenile bipolar disorder: a retrospective chart review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Acute treatment of bipolar disorder with adjunctive risperidone in outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Treatment with atypical antipsychotics: new indications and new populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Use of olanzapine in dysphoric mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Clozapine in the treatment of refractory psychotic mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Efficacy of antipsychotics in the treatment of the behavioral complications of dementia: a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Risperidone for the treatment of behavioral disturbances in dementia: a case series

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome--a functional approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Efficacy of SSRIs and Newer Antidepressants in Severe Depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Clozapine as add-on medication in the maintenance treatment of bipolar and schizoaffective disorders. A case series

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Risperidone treatment of behavioral disturbances in outpatients with dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Olanzapine in acute bipolar mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Risperidone for treating dementia-associated aggression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Psychiatric illnesses in the elderly: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Improvement of both psychotic symptoms and Parkinsonism in a case of dementia with Lewy bodies by the combination therapy of risperidone and L-DOPA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

A case report of refractory obsessive-compulsive disorder improved by risperidone augmentation of clomipramine treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Response to treatment with antidepressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

The use of risperidone in severely demented patients with persistent vocalizations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Course of the Manic-Depressive Cycle and Changes Caused by Treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Efficacy and safety of neuroleptics in behavioral disorders associated with dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Risperidone monotherapy for psychotic depression unresponsive to other treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Psychotic symptoms and vulnerability to recurrent major depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Fixed-dosed risperidone in mania: an open experimental trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Delusional depression: phenomenology and response to treatment. A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Olanzapine and obsessive-compulsive symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Obsessional symptoms associated with risperidone treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Clozapine in the management of bipolar and schizoaffective manic episodes resistant to standard treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Olanzapine in the treatment of psychotic depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Antidepressant augmentation with low-dose olanzapine in obsessive-compulsive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Pharmacologic agents for the treatment of acute bipolar mania.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Olanzapine in treatment-resistant bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Comparison of clinical characteristics in obsessive-compulsive disorder and body dysmorphic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Delusional unipolar depression: description and drug response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Psychotic (delusional) depression: a meta-analysis of physical treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Efficacy and safety of fluvoxamine in body dysmorphic disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Pharmacologic treatment of agitation associated with dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Olanzapine response in psychotic depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Bipolar disorder therapeutics: maintenance treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

A metaanalysis of controlled trials of neuroleptic treatment in dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Manic symptoms associated with initiation of risperidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

A novel augmentation strategy for treating resistant major depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

The pharmacological treatment of delusional depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Clozapine in the treatment of dysphoric mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Long-Term use of quetiapine in elderly patients with psychotic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Olanzapine versus divalproex in the treatment of acute mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

7 January 2021

Respiridone and mania

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Somatic treatment of psychotic depression: review and recommendations for practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Treatment of Refractory Rapid Cycling Bipolar Disorder With Risperidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Adjunctive Use of Olanzapine in Mood Disorders: Five Case Reports

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

Overview of depression and psychosis in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

7 January 2021

Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

7 January 2021

A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

7 January 2021

Risperidone in the treatment of patients with Alzheimer's disease with negative symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

7 January 2021

Quetiapine alone and added to a mood stabilizer for serious mood disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

7 January 2021

Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

7 January 2021

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

7 January 2021

Cognitive-behavioral body image therapy for body dysmorphic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2803%2900094-3

7 January 2021

10.1016/S0022-3956(03)00094-3

Identifiers

DOI

1 reference

9 August 2017

1 reference